Last reviewed 2026-05-27 · How we verify

EBANGA (ANSUVIMAB-ZYKL)

RIDGEBACK BIOTHERAPEUTICS · FDA-approved approved ✓ Verified May 2026 Quality 19/100

EBANGA (generic name: ANSUVIMAB-ZYKL) is a drug developed by RIDGEBACK BIOTHERAPEUTICS. It is currently FDA-approved for Ebola virus disease.

Ansuvimab is a monoclonal antibody used as a therapeutic or for post-exposure prophylaxis (PEP) in patients with Ebola Virus Disease. It works by binding to the envelope glycoprotein of the Ebola virus.

At a glance

Generic name	ANSUVIMAB-ZYKL
Sponsor	RIDGEBACK BIOTHERAPEUTICS
Target	Envelope glycoprotein
Therapeutic area	Metabolic
Phase	FDA-approved

Approved indications

Ebola virus disease

Common side effects

Pyrexia
Tachycardia
Diarrhea
Vomiting
Hypotension
Tachypnea
Chills
Hypoxia
Abdominal pain

Serious adverse events

Potassium, high (≥ 6.5 mmol/L)
Sodium, low (< 125 mmol/L)
Sodium, high (≥ 154 mmol/L)

Drug interactions

Live vaccine indicated for prevention of Zaire ebolavirus infection

Key clinical trials

Open-Label, Expanded Access Protocol of a Human Monoclonal Antibody, Ansuvimab (mAb114), Administered As a Therapeutic to Ebola-Infected Patients or As a High-Risk Ebola Post-Exposure Prophylaxis (N/A)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EBANGA CI brief — competitive landscape report
EBANGA updates RSS · CI watch RSS
RIDGEBACK BIOTHERAPEUTICS portfolio CI

Frequently asked questions about EBANGA

What is EBANGA?

EBANGA (ANSUVIMAB-ZYKL) is a pharmaceutical drug developed by RIDGEBACK BIOTHERAPEUTICS, indicated for Ebola virus disease.

What is EBANGA used for?

EBANGA is indicated for Ebola virus disease.

Who makes EBANGA?

EBANGA is developed and marketed by RIDGEBACK BIOTHERAPEUTICS (see full RIDGEBACK BIOTHERAPEUTICS pipeline at /company/ridgeback-biotherapeutics).

What is the generic name of EBANGA?

ANSUVIMAB-ZYKL is the generic (nonproprietary) name of EBANGA.

What development phase is EBANGA in?

EBANGA is FDA-approved (marketed).

What are the side effects of EBANGA?

Common side effects of EBANGA include Pyrexia, Tachycardia, Diarrhea, Vomiting, Hypotension, Tachypnea. Serious adverse events: Potassium, high (≥ 6.5 mmol/L), Sodium, low (< 125 mmol/L), Sodium, high (≥ 154 mmol/L).

What does EBANGA target?

EBANGA targets Envelope glycoprotein.

Target: All drugs targeting Envelope glycoprotein
Manufacturer: RIDGEBACK BIOTHERAPEUTICS — full pipeline
Therapeutic area: All drugs in Metabolic
Indication: Drugs for Ebola virus disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing